No sooner does one gammadelta-focused biotech die than another takes its place.
ApexOnco Front Page
Recent articles
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
First-in-human results prompt a biomarker-defined approach for CID-078.
The company’s conjugate QLS5132 has produced intriguing, but early results.
Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
A son of glembatumumab vedotin has just started its phase 1 study.
Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
